ICU-Acquired Weakness & Neuromuscular Emergencies

📘 1 · Washington Manual of Critical Care

Two Very Different Questions About a Weak Patient

Weakness in the ICU comes in two forms that must not be confused. The first is acquired in the unit — critical illness polyneuropathy and myopathy (ICU-acquired weakness), a symmetrical limb and respiratory weakness that develops during a prolonged critical illness and impedes weaning. The second is the weakness that brings the patient into the unit — Guillain-Barré syndrome and myasthenic crisis — where the threat is acute neuromuscular respiratory failure. The first is managed by prevention and rehabilitation; the second is a neurological emergency where the airway can be lost while the blood gas still looks reassuring.

Summarised from the Washington Manual of Critical Care — Neuromuscular Disorders in the ICU.

The bedside approach

Pattern & time-course — did the weakness develop during the ICU stay (think CIP/CIM) or precede/precipitate admission (think GBS, myasthenia, others)?
Localise — nerve (GBS, CIP), neuromuscular junction (myasthenia, botulism, organophosphate), or muscle (CIM). Reflexes and sensory signs help.
Screen for mimics — high spinal cord lesion, electrolyte disturbance (↓K⁺, ↓PO₄, ↓Mg²⁺, ↑/↓Ca²⁺), prolonged neuromuscular blockade, hypothyroid/steroid myopathy, periodic paralysis.

📗 2 · Marino's The ICU Book, 5th Edition (2025)

ICU-Acquired Weakness — Prevent It, Because You Can't Treat It

Critical illness polyneuropathy and myopathy develop in a large proportion of patients ventilated for more than a week, especially in the setting of sepsis, multi-organ failure and prolonged immobility. There is no specific drug cure once it is established; the entire therapeutic strategy is preventive — aggressive treatment of sepsis, avoidance of the drugs and states that damage nerve and muscle, minimisation of sedation, and getting the patient moving. The single most important reversible contributor is the combination that we control: deep sedation, immobility, and hyperglycaemia.

Summarised from Marino PL. The ICU Book, 5th Ed — Critical Illness Neuromyopathy.

🔬 Risk factors → ICU-acquired weakness

DriverSepsis · SIRS · multi-organ failure

Prolonged immobility & deep sedation

Hyperglycaemia

Corticosteroids · aminoglycosides · prolonged NMB

Axonal polyneuropathy (CIP) and/or myopathy (CIM) — symmetrical, flaccid, diaphragm involved

ConsequenceFailure to wean · prolonged ventilation · long-term disability

📗 Marino — the prevention bundle that works

Treat sepsis aggressively and reverse organ failure — the primary driver.
Minimise sedation (daily interruption / light targets), avoid unnecessary neuromuscular blockade, and mobilise early — the strongest evidence-based intervention.
Avoid hyperglycaemia, and limit aminoglycosides/steroids where possible. Diagnosis is largely clinical (MRC sum score <48/60); nerve-conduction studies confirm and exclude mimics like GBS.

📋 3 · GBS & Myasthenic Crisis — the Emergencies

Evidence-Based Management

🔵 Guillain-Barré syndrome (GBS)

Ascending, symmetrical flaccid weakness + areflexia, often post-infective (Campylobacter, viral)
Autonomic instability (arrhythmia, BP swings), bulbar & respiratory failure
CSF: albumino-cytological dissociation; NCS confirm
Treat: IVIg OR plasma exchange (equally effective; do NOT combine); steroids do NOT work

🟣 Myasthenic crisis

Fatigable weakness, ptosis, diplopia, bulbar & respiratory failure
Precipitants: infection, surgery, certain drugs (aminoglycosides, fluoroquinolones, β-blockers, magnesium)
Treat: IVIg OR plasma exchange + corticosteroids (watch initial worsening) + continue/optimise immunotherapy
Distinguish from cholinergic crisis (excess anticholinesterase)

Watch the breathing — intubate on the trend, not the ABG STRONG

In GBS and myasthenic crisis, respiratory failure is neuromuscular: the patient tires and the vital capacity falls before the CO₂ rises. Monitor forced vital capacity (FVC) and negative inspiratory force serially — the classic "20/30/40 rule" (FVC <20 mL/kg, NIF weaker than −30 cmH₂O, maximal expiratory pressure <40) signals impending failure and the need for elective, controlled intubation. A normal or only mildly abnormal blood gas is falsely reassuring — do not wait for hypercapnia. Watch bulbar failure (secretions, aspiration) too.

Immunotherapy — IVIg or plasma exchange STRONG

IVIg (0.4 g/kg/day for 5 days) or plasma exchange are the disease-modifying treatments for both GBS and myasthenic crisis and are equally effective; choose by availability, access and comorbidity — do not combine them in GBS (no added benefit). In myasthenic crisis, add/continue corticosteroids (warn of transient early worsening) and optimise chronic immunotherapy; treat the precipitant and review the drug chart for agents that worsen neuromuscular transmission.

Supportive care determines outcome

Meticulous ICU support: airway/ventilation, aspiration prevention, autonomic monitoring (GBS — labile BP/arrhythmia; avoid over-treating transient swings), VTE prophylaxis, pain and pressure-area care, nutrition, and early rehabilitation/physiotherapy. Avoid succinylcholine in established neuromuscular disease/immobility (hyperkalaemia risk); use non-depolarising agents cautiously and expect altered sensitivity.

🇮🇳 Indian Context

Neuromuscular emergencies with a distinctly Indian flavour include organophosphate/carbamate poisoning (cholinergic crisis → the intermediate syndrome with proximal and respiratory weakness — see Toxicology in the ICU), neuroparalytic snakebite (cobra/krait — descending paralysis and ptosis; antivenom ± neostigmine, and a low threshold to ventilate — see Snakebite), and hypokalaemic periodic paralysis. GBS is common and IVIg, though effective, is expensive — plasma exchange is an equally effective and often more accessible alternative in Indian units and should be used where IVIg is unaffordable or unavailable. For ICU-acquired weakness, the highest-value, lowest-cost interventions — sepsis control, sedation minimisation, glucose control and early mobilisation — are available everywhere.

💊 4 · Drug Doses

Immunotherapy & Supportive Agents

Drug / Measure	Indication	Dose	Notes
IVIg	GBS or myasthenic crisis	0.4 g/kg/day IV for 5 days (total 2 g/kg)	Equal to PLEX; check IgA (anaphylaxis), thrombosis/renal caution; do not combine with PLEX in GBS
Plasma exchange (PLEX)	GBS or myasthenic crisis	~5 exchanges over 1–2 weeks	Equally effective; often more accessible/affordable than IVIg
Corticosteroids	Myasthenic crisis (NOT GBS)	Prednisolone/methylprednisolone per protocol	Transient early worsening in MG; ineffective/harmful in GBS
Pyridostigmine	Myasthenia — symptomatic	Oral, titrated	Often held in crisis (secretions); watch cholinergic crisis
FVC / NIF monitoring	Predict respiratory failure	Serial bedside spirometry	"20/30/40 rule" → elective intubation; don't wait for hypercapnia
Avoid succinylcholine	Established NM disease / immobility	—	Hyperkalaemic arrest risk; use non-depolarisers cautiously
Early mobilisation / physiotherapy	Prevent & recover ICU-AW	Structured daily programme	Strongest intervention for ICU-acquired weakness

🗺 5 · Clinical Flowchart

Approach to Weakness in the ICU

When did the weakness start?

Developed in ICU (prolonged vent, sepsis) → think CIP/CIM (ICU-acquired weakness)
Brought the patient in / precipitated admission → think GBS, myasthenic crisis, toxin, snakebite

Protect the airway — monitor mechanics

Serial FVC/NIF; bulbar function; "20/30/40 rule" → elective intubation
Do not wait for a rising CO₂ — neuromuscular failure tires first

Diagnose & exclude mimics

Reflexes/sensory exam, CSF (albumino-cytological dissociation in GBS), NCS/EMG, anti-AChR/MuSK
Correct electrolytes; review drugs (NMB, aminoglycosides); consider spinal cord, toxin, periodic paralysis

Treat the specific cause

GBS / myasthenic crisis → IVIg OR plasma exchange (steroids for MG, not GBS)
ICU-acquired weakness → prevention bundle: sepsis control, sedation minimisation, glucose control, early mobilisation

Support & rehabilitate

Autonomic monitoring (GBS), VTE prophylaxis, nutrition, pressure care, physiotherapy
Anticipate prolonged weaning; structured rehabilitation determines long-term function

⚠️ 6 · Common Mistakes

Common Mistakes in ICU Weakness

❌ Mistake 1 — Waiting for a rising CO₂ to intubate in GBS/myasthenia

Neuromuscular respiratory failure tires the patient and drops the vital capacity before the blood gas deteriorates. Monitor FVC/NIF and intubate electively on the trend (20/30/40 rule).

❌ Mistake 2 — Giving steroids for GBS

Corticosteroids are ineffective (and potentially harmful) in GBS. Treat with IVIg or plasma exchange — not both.

❌ Mistake 3 — Combining IVIg and plasma exchange in GBS

There is no added benefit to combining them; choose one based on access and comorbidity.

❌ Mistake 4 — Missing the myasthenia drug precipitants

Aminoglycosides, fluoroquinolones, β-blockers and magnesium can precipitate or worsen a myasthenic crisis. Review the chart and stop the offenders.

❌ Mistake 5 — Using succinylcholine in established weakness/immobility

Up-regulated receptors risk hyperkalaemic cardiac arrest. Avoid succinylcholine; use non-depolarisers cautiously with altered sensitivity.

❌ Mistake 6 — Treating ICU-acquired weakness as something you can drug away

There is no specific cure once established. The whole strategy is prevention — treat sepsis, minimise sedation and NMB, control glucose, and mobilise early.

🎓 7 · Exam Pearls — DrNB / PDCC / IFCCM / EDIC

Exam Pearls

Q: What is ICU-acquired weakness and how is it managed?
Critical illness polyneuropathy/myopathy from sepsis, immobility, hyperglycaemia and prolonged sedation/NMB — no specific cure; managed by prevention and early mobilisation (MRC sum score <48/60).

Q: When do you intubate in GBS or myasthenic crisis?
Electively on serial mechanics — FVC <20 mL/kg, NIF weaker than −30, MEP <40 ("20/30/40 rule") — not on the blood gas, which lags.

Q: What is the treatment of GBS?
IVIg or plasma exchange (equally effective, do not combine); steroids do not work in GBS.

Q: How does myasthenic crisis treatment differ from GBS?
Same first-line (IVIg or PLEX) but corticosteroids ARE used in MG (watch initial worsening), plus optimise chronic immunotherapy and remove precipitant drugs.

Q: CSF finding in GBS?
Albumino-cytological dissociation (raised protein, normal cell count).

Q: Which relaxant is dangerous in these patients?
Succinylcholine — risk of hyperkalaemic arrest from up-regulated acetylcholine receptors.

Q: Indian neuromuscular emergencies to consider?
Organophosphate poisoning (intermediate syndrome), neuroparalytic snakebite, and hypokalaemic periodic paralysis; PLEX is a cost-effective alternative to IVIg.

📚 8 · References

References

Stevens RD, Marshall SA, Cornblath DR, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med. 2009;37(Suppl):S299–S308.
Hermans G, Van den Berghe G. Clinical review: intensive care unit acquired weakness. Crit Care. 2015;19:274.
Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15:671–683.
Wendell LC, Levine JM. Myasthenic Crisis. Neurohospitalist. 2011;1:16–22.
Marino PL. The ICU Book, 5th Edition. Neuromuscular Disorders / Critical Illness Neuromyopathy. Wolters Kluwer; 2025.
Washington Manual of Critical Care, 4th Edition. Kollef MH, Witt CA (eds). Neuromuscular Disorders. Wolters Kluwer; 2023.